Cathelijne Fokkema, MD^1*, Madelon M.E. de Jong, MD^1*, Sabrin Tahri, MD^1*, Zoltan Kellermayer, MD, PhD^1*, Chelsea den Hollander, BSc^1*, Michael Vermeulen, BSc^1*, Natalie Papazian^1*, Mark van Duin, PhD^1*, Michiel J.W. Wevers, MSc^1*, Mathijs A. Sanders, PhD, MSc^1*, Vincent H.J. van der Velden, PhD^2*, Pieter Sonneveld¹, Annemiek Broyl^1* and Tom Cupedo, PhD^1*

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Department of Immunology, Laboratory Medical Immunology, Erasmus University Medical Center, Rotterdam, Netherlands

Selina J Chavda, MBBS, BSc, MRCP, FRCPATH^1*, Daria Galas-Filipowicz^2*, Evelyn Fitzsimons, BSc^1*, Anna Mikolajczak, BSc, MSc^1*, Sharon Tooze, PhD, Professor^3*, Holger W Auner, MD, PhD⁴, Katja Simon, PhD^5*, Asim Khwaja, MD, FRCP, FRCPATH^1* and Kwee Yong, MD, PhD^1*

¹Cancer Institute, Department of Haematology, University College London, London, United Kingdom
²Cancer Institute, Department of Haematology, UCL, London, United Kingdom
³Francis Crick Institute, London, United Kingdom
⁴Imperial College London, London, United Kingdom
⁵University of Oxford, Oxford, United Kingdom

Niels Van Nieuwenhuijzen, MD^1,2*, Marta Cuenca, PhD^1*, Leonie Abbink^2*, Eline Lammers, MD^2*, Margot Jak, MD, PhD^2*, Victor Peperzak, PhD^1* and Monique C. Minnema, MD²

¹Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
²Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

Mariah Farrell, MS^1,2,3*, Heather Fairfield, MS^1,2,3*, Anastasia D'Amico, BS^1*, Connor S Murphy, BS^1,4*, Carolyne Falank, PhD^1*, Catherine R. Marinac, PhD⁵, Romanos Sklavenitis-Pistofidis, MD⁶, Amanda Cao^7*, Julie Dragon, PhD^8* and Michaela R Reagan, PhD^2,3,9

¹Maine Medical Center Research Institute, Scarborough, ME
²Tufts University School of Medicine, Boston, MA
³University of Maine, Orono, ME
⁴Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Dana-Farber Cancer Institute, Boston, MA
⁸University of Vermont, Burlington, VT
⁹Maine Medical Center Research Institute, South Portland, ME

Roisin M McAvera^*, Jonathan J Morgan, BSc, MRes^*, Ken I Mills and Lisa J Crawford, BSc, PhD^*

Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom

Jonas Schwestermann, MSc^1*, Andrej Besse, PhD^1*, Lenka Besse, PhD^1* and Christoph Driessen, MD²

¹Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
²Laboratory of Experimental Oncology, Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Shiqiao Ye, PhD, BSc, MSc^1*, Yu Chen^1*, Bo Hu, PhD^1*, Huayu Huang, MSc^1*, Yuxiao Sun, MD. PhD^1*, James P Stewart, PhD^1*, Sarah K Johnson, PhD^1*, Bart Barlogie, MD.PhD^2*, Maurizio Zangari, MD, FACP¹, Guido Tricot, MD. PhD^1*, Faith E Davies, MD³, Gareth J Morgan, MD, PhD^3*, Brian A Walker, PhD⁴, Fenghuang Zhan, MD. PhD¹, Frits van Rhee, MD PhD², John D Shaughnessy Jr., PhD^1* and Ya-Wei Qiang, MD, PhD¹

¹Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
³Perlmutter Cancer Center, NYU Langone Health, New York, NY
⁴Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN

Natthakan Thongon, PhD¹, Andrea Santoni, PhD^1*, Jintan Liu, PhD^2*, Natalia Baran, PhD, MD¹, Feiyang Ma, PhD^3*, Christopher Jackson, BS^1*, Pamela Lockyer, MS^1*, Irene Ganan-Gomez, PhD¹, Vera Adema, PhD^1*, Ashley Rose, MD⁴, Matteo Marchesini, PhD^1,5*, Yun Qing, PhD^6*, Min Jin Ha, PhD^6*, Caleb Class, PhD^6*, Matteo Pellegrini, PhD^3*, Lin Tan^7*, Philip Lorenzi, PhD⁸, Marina Konopleva, MD, PhD¹ and Simona Colla, PhD^1*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Molecular Biology Institute, Molecular Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, CA
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Tampa, FL
⁵Department of Medicine and Surgery, University of Parma, Parma, Italy
⁶Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Bioinformatics and Computational Biology and The Proteomics and Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Inge Oudaert, MSc^1*, Hatice Satilmis^1*, Philip Vlummens, MD^1,2*, Anke Maes, PhD^1*, Elke De Bruyne, PhD^1*, Karin Vanderkerken, PhD¹, Sarah-Maria Fendt, PhD^3,4*, Kim De Veirman, PhD^1* and Eline Menu, PhD^1*

¹Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
²UZ Gent, Gent, Belgium
³Laboratory of Cellular Metabolism and Metabolic Regulation, VIB, Leuven, Belgium
⁴Laboratory of Cellular Metabolism and Metabolic Regulation, UZ Leuven, Leuven, Belgium

Chao Zhang, PhD^1,2*, Xiaoxuan Xu, MD^1*, Timothy Trotter, PhD^1*, Amjad Javed, PhD^3,4*, Joanne E. Murphy-Ullrich, PhD^1*, Juan Li, PhD² and Yang Yang, MD^1,4

¹Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
²First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
³Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, AL
⁴Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL

Maria Moscvin^1*, Tianzeng Chen, MS^2*, Peter G. Czarnecki, MD^3*, Annamaria Gulla, MD⁴, Kenneth C. Anderson, MD⁵ and Giada Bianchi, MD^2,6

¹Brigham and Women's Hospital, Boston, MA
²Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
³Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
⁴Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁵Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
⁶Harvard Medical School, Boston, MA

Andrej Besse, PhD^1*, Lenka Besse, PhD^1*, Lorina Büchler^1*, Sara C. Stolze^2*, Amin Sobh, PhD³, Marianne Kraus^1*, Hirofumi Nakagami^2* and Christoph Driessen, MD⁴

¹Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
²Protein Mass Spectrometry Group, Max Planck Institute for Plant Breeding Research, Cologne, Germany
³Cancer and Genetics Research Complex, University of Florida, Gainesville, FL
⁴Laboratory of Experimental Oncology, Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Sabrin Tahri, MD^1*, Zoltan Kellermayer, MD, PhD^1*, Madelon M.E. de Jong, MD^1*, Natalie Papazian^1*, Cathelijne Fokkema, MD^1*, Chelsea den Hollander, BSc^1*, Pieter van de Woestijne, MD PhD^2*, Mark van Duin, PhD^1*, Annemiek Broijl, MD, PhD^1*, Pieter Sonneveld¹ and Tom Cupedo, PhD^1*

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Department of Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands

Sebastian Köhrer^1,2*, Tobias Dittrich, MD^1,2,3,4*, Martin Schorb, PhD^5*, Niels Weinhold, PhD^3*, Isabella Haberbosch, MD^2,3*, Mandy Börmel, PhD^5*, Gabor Pajor, PhD^2*, Hartmut Goldschmidt^3,6, Carsten Müller-Tidow, MD^3,6*, Marc-Steffen Raab^2,3*, Alexander Brobeil, MD^7*, Peter Dreger, MD³, Ute Hegenbart, MD^4,8*, Stefan Schönland^3,4*, Yannick Schwab, PhD^1,5* and Alwin Krämer, MD^2,3*

¹Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
²Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
³Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
⁴Amyloidosis Center, University of Heidelberg, Heidelberg, Germany
⁵Electron Microscopy Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
⁶National Center for Tumor Diseases (NCT), University of Heidelberg, Heidelberg, Germany
⁷Institute of Pathology, University of Heidelberg, Heidelberg, Germany
⁸Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-W., Germany

Yawara Kawano, MD, PhD¹, Saki Kushima^2*, Hiroyuki Hata, MD, PhD,³ and Masao Matsuoka, MD, PhD⁴

¹Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan
²Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
³Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University School of Health Science, Kumamoto, Japan
⁴Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan

Danielle C Croucher, MSc^1,2*, Laura M Richards^1,2*, Zhihua Li, MSc^1*, Ellen nong Wei, Msc^1*, Xian Fang Huang^3*, Daniel Waller, PhD^3*, Marta Chesi, PhD⁴, P. Leif Bergsagel, MD⁵, Michael Sebag, MD, PhD⁶, Trevor J. Pugh, PhD^1,2,7* and Suzanne Trudel, MD^1,2

¹Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
²Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
³McGill University Health Centre, Montreal, QC, Canada
⁴Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
⁵Division of Hematology, Mayo Clinic, Scottsdale, AZ
⁶Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
⁷Ontario Institute for Cancer Research, Toronto, Canada

Laure Dutrieux^1*, Yea-Lih Lin, PhD^2*, Malik Lutzmann, PhD^2*, Guilhem Requirand^3*, Nicolas Robert^3*, Laure Vincent, MD^4*, Guillaume Cartron, MD, PhD^5,6,7,8*, Charles Herbaux, MD⁹, Raphael Rodriguez^10*, Michel Cogne^11*, Philippe Pasero, PhD^2* and Jerome Moreaux, PhD^2,3,12,13

¹Institute of human genetics, UMR CNRS-UM 9002, Montpellier, France
²Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
³Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
⁴CHU de Montpellier / Département d'hématologie clinique, Hôpital Saint-Eloi, Montpellier, France
⁵Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
⁶Montpellier University, UMR CNRS 5235, Montpellier, France
⁷Hematology Department, Montpellier University Hospital, Montpellier, France
⁸Department of Clinical Hematology and Unite Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), CHRU, Montpellier, France
⁹Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
¹⁰Institut Curie, Paris, France
¹¹Centre National De La Recherche Scientifique UMR CNRS 7276/INSERM U1262, Univers, LIMOGES, FRA
¹²UFR Médecine, Université Montpellier, Montpellier, France
¹³Institut Universitaire de France, Paris, France

Melissa Vrohlings^1*, Jan Müller, MD^2*, Stephanie Jungmichel^1*, David Senn^1*, Anna Bianca Howald^1*, Thomas Schleier^1*, Fabian Scheifele^1*, Severin Wendelspiess^1*, Philipp Richle^1*, Hannes Merten^1*, Daniel Lenherr-Frey^1*, Christian Leisner^1*, Markus G Manz, MD² and Leonardo J. Borras^1*

¹CDR-Life Inc, Schlieren, Switzerland
²Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

Ling-Ling Shu, PhD¹, Shuzhao Chen^2*, Jinyuan Li^1*, Weida Wang, MD, PhD^1*, Yang Liu^3*, Yang Li^4*, Han-Ying Huang^5*, Xiaoping Wu^6* and Yang Liang, MD, PhD⁷

¹State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, AL, China
³Zhujiang Hospital, Southern Medical University, Guangzhou, CHN
⁴Sun Yat-Sen University Cancer Center, Guangzhou, CHN
⁵Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology In South, Guangzhou, China
⁶State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kon, Hong Kong, CHN
⁷State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China

David M Foureau, PhD¹, Manisha Bhutani, MD², Fei Guo, PhD^2*, Kateryna Fesenkova^2*, Shebli Atrash, MD³, Reed Friend, MD³, Barry Paul, MD, MS⁴, Myra M Robinson, MSPH^5*, James T Symanowski, PhD^6*, Lawrence J Druhan, PhD⁷, Mauricio Pineda-Roman, MD³, Peter M. Voorhees, MD³ and Saad Z. Usmani, MD MBA FACP³

¹Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC
²Levine Cancer Institute, Atrium Health, Charlotte, NC
³Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁴Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁵Levine Cancer Institute, Charlotte, NC
⁶Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁷Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC

Amin Sobh, PhD^1,2, Charlotte L Kaestner, BS¹, Jianping Li, MD¹, Alberto Riva, PhD^2*, Richard Lynn Bennett, PhD¹ and Jonathan D. Licht, MD¹

¹Department of Medicine, University of Florida, Gainesville, FL
²Cancer and Genetics Research Complex, University of Florida, Gainesville, FL

Pooja Shah, MSc^1*, Thorsten Stuehmer, PhD^2*, Daniela Bruennert, PhD^3*, Umair Munawar, PhD^1*, Ellen Leich, PhD^4*, Sabrina Kraus, MD^1*, Michael Hudecek, MD^1*, Manik Chatterjee, MD^2*, Andreas Schlosser, PhD^5*, Ralf C Bargou, MD^2*, Hermann Einsele¹, Friederike Berberich-Siebelt, PhD^4* and Torsten Steinbrunn^1*

¹Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
²Comprehensive Cancer Center Mainfranken, University Hospital of Wuerzburg, Wuerzburg, Germany
³Department of Obstetrics and Gynecology, University Hospital of Wuerzburg, Wuerzburg, Germany
⁴Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
⁵Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany

Munevver Cinar, MD^1*, Badri Vardarajan, PhD^2*, Neil Anthony, PhD^3*, Bassel El-Rayes, MD^3*, Ganji Nagaraju^4*, Lourdes Martinez-Medina, PhD^5*, Jean-Michel Gries, PharmD^6* and Leon Bernal-Mizrachi, MD⁷

¹Emory University Winship Cancer Institute/ Department of Hematology and Medical Oncology, Atlanta, GA
²Kodikaz Therapeutic Solutions, LLC, new york, NY
³Winship Cancer Institute of Emory University, atlanta, GA
⁴Winship Cancer Institute of Emory University, Atlanta, GA
⁵Kodikaz Therapeutic Solutions, new york, NY
⁶Kodikaz Therapeutic Solutions, New York, NY
⁷Winship Cancer Institute/Department of Hematology and Medical Oncology, Emory University, atlanta, GA

Ricardo De Matos Simoes, PhD^1,2*, Benjamin G Barwick, PhD³, Ryosuke Shirasaki, MD^1,2,4*, Olga Dashevsky, PhD^1,2*, Sara Gandolfi, MD, PhD^1,2,5*, Huihui Tang, PhD^1,2*, Brian Glassner, PhD^1,2*, Richard W.J. Groen, PhD⁶, Daniel Auclair, PhD⁷, Aedin Culhane, PhD^8*, Aviad Tsherniak, PhD^2*, Francisca Vazquez, Phd^2*, Jonathan D. Licht, MD⁹, Lawrence H. Boise, PhD¹⁰ and Constantine S. Mitsiades, MD, PhD^1,2

¹Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Broad Institute of MIT and Harvard, Cambridge, MA
³Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
⁴Dept. of Medical Oncology, Teikyo university hospital, Tokyo, TKY, Japan
⁵Translational Immunology Research program, University of Helsinki, Helsinki, MA, Finland
⁶University Medical Center Utrecht, Amsterdam, Netherlands
⁷Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
⁸Dept. of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Department of Medicine, University of Florida, Gainesville, FL
¹⁰Emory University, Atlanta, GA

Mehmet K. Samur, PhD^1,2, Anil Aktas-Samur, PhD^3*, Romain Lannes, PhD^4*, Jill Corre^4*, Anjan Thakurta, PhD^5*, Kenneth C. Anderson, MD⁶, Herve Avet-Loiseau^7* and Nikhil C. Munshi, MD, PhD⁸

¹Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
²Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
⁴Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
⁵Translational Medicine, Bristol Myers Squibb, Summit, NJ
⁶Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
⁷Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston

Ting DU, PhD^1*, Yan Song, PhD^1*, Arghya Ray, PhD¹, Ruben D. Carrasco, MD, PhD^2*, Sirano Dhe-Paganon, PhD^1*, Dharminder Chauhan, PhD^1* and Kenneth C. Anderson, MD³

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA
³LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Gemma Martinez-Rivas^1*, Maria Ayala^2*, Sebastien Bender, PhD^3*, Michael Ehrmann^4*, Murielle Roussel, MD^1,5*, Arnaud Jaccard^6,7*, Frank Bridoux, MD^8* and Christophe Sirac^7*

¹CRIBL Lab, CNRS UMR7276 INSERM U1262, CNRS, INSERM, University of Limoges, Limoges, France
²UMR CNRS7276 INSERM1262, University of Limoges, LIMOGES, FRA
³CRIBL Lab, University Hospital Limoges, LIMOGES, FRA
⁴Center of Medical Biotechnology (ZMB), Faculty of Biology, University of Duisburg-Essen, Essen, Germany
⁵hematology, CHU de Limoges, Limoges, France
⁶CRIBL Lab, Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
⁷CRIBL laboratory, CNRS UMR6101, Limoges, France
⁸CRIBL Laboratory, CHU Poitiers, CNRS UMR7276, Poitiers, FRA

Seth Welsh, PhD^1*, Daniel Riggs, PhD^1*, Erin Meermeier, PhD^1*, Chang-Xin Shi, PhD^1*, Victoria Garbitt^1*, Meaghen E Sharik, BS^1*, Megan Du^1*, Kennedi Todd^1*, Zachary Hammond^1*, Sochilt Brown^1*, Caleb K Stein, PhD^1*, Paola Neri, MD, PhD², Nizar J. Bahlis, MD², Benjamin G Barwick, PhD³, Larry H. Boise, PhD⁴, W. Michael Kuehl, MD, PhD^5*, Marta Chesi, PhD¹ and P. Leif Bergsagel, MD¹

¹Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
²Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
³Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
⁴Winship Cancer Institute, Emory University, Atlanta, GA
⁵National Cancer Institute, National Institutes of Health, Bethesda, MD

Rong Fan^1*, Hatice Satilmis^1*, Niels Vandewalle^1*, Elke De Bruyne, PhD^1*, Eline Menu, PhD^1*, Andrew D Chantry, PhD, MD^2*, Holly Evans, BSc^2*, Marie Törngren^3*, Helena Eriksson, PhD^3*, Karine Breckpot, PhD^4*, Ken Maes, PhD^1*, Karin Vanderkerken, PhD¹ and Kim De Veirman, PhD^1*

¹Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
²Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom
³Active Biotech AB, Lund, Sweden
⁴Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium

Mary Sartor, BSc, PhD^1*, Daniel Y Hu, PhD^1*, Thomas X Lemarchand, DVM DESV-AP PhD DECVP^2*, Luise Britz, BSc MSc PhD^2*, Rosanne Dunn, PhD^3* and David J Gottlieb, MD, MBBS, FRACP, FRCPA^4*

¹Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia
²TPL Path Labs GmbH, Freiburg, Germany
³Haemalogix Pty Ltd, Woolloomooloo, NSW, Australia
⁴Department of Haematology, Westmead Hospital, Sydney, Australia

Camila Guerrero^1*, Noemi Puig, MD, PhD², María Teresa Cedena, MD, PhD^3*, Ibai Goicoechea, PhD¹, Cristina Pérez Ruiz^1*, Juan José Garcés^1*, Cirino Botta, MD, PhD⁴, Maria Jose Calasanz, PhD, BSc^1*, Norma C. Gutierrez^2*, Maria Luisa Martin-Ramos^3*, Albert Oriol^5*, Rafael Rios, MD, PhD^6*, Miguel Hernández^7*, Rafael Martínez, M.D.^8*, Joan Bargay^9*, Felipe De Arriba, PhD^10*, Luis Palomera, MD, PhD^11*, Ana Pilar Gonzalez, PhD^12*, Adrián Mosquera Orgueira^13*, Marta Sonia Gonzalez, MD^13*, Joaquín Martínez-López^3*, Juan Jose Lahuerta, MD, PhD^3*, Laura Rosinol^14*, Joan Bladé Creixenti¹⁵, Maria-Victoria Mateos², Jesus San-Miguel¹ and Bruno Paiva, PhD^1*

¹Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
²Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
³Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy
⁵Institut Català d'Oncologia L’Hospitalet, Barcelona, Spain
⁶Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
⁸Hospital Universitario San Carlos, Madrid, Spain
⁹Hospital Universitario Son Llatzer, Institut d’ investigacio Illes Balears (IdISBa), Palma de Mallorca, Spain
¹⁰Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
¹¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
¹²Hospital Central de Asturias, Oviedo, Spain
¹³Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
¹⁴Hematology Department, IDIBAPS, Hospital Clínic, Barcelona, Spain
¹⁵Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clínic, Barcelona, Spain, Barcelona, Spain

Raija Helena Silvennoinen, MD^1,2, Komal Kumar Javarappa, PhD³, Sini Luoma, MD^1*, Philipp Sergeev, MSc^4*, Tiina J Öhman^5*, Markku Varjosalo^5*, Pekka Anttila, MD^1*, Marjaana Säily, MD, PhD^6*, Anu Partanen, MD, PhD^2*, Marja Sankelo, MD, PhD^7* and Caroline A. Heckman, PhD⁴

¹Helsinki University Hospital, Comprehensive Cancer Center Hematology and University of Helsinki, Helsinki, Finland
²Department of Medicine, Kuopio University Hospital, Kuopio, Finland
³Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
⁴Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
⁵CyTOF Unit, Viikki Campus, Helsinki, Finland
⁶Department of Internal Medicine, Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland
⁷Department of Hematology, Tampere University Hospital, Tampere, Finland

Osman Aksoy^1*, Judith Lind, PhD^1*, Vincent Sunder-Plassmann^1*, Martin Percherstorfer, MD^2*, Sonia Vallet, MD, PhD^2* and Klaus Podar, MD, PhD^1,2

¹Karl Landsteiner University of Health Sciences, Krems, Austria
²Department of Internal Medicine II, University Hospital Krems, Krems, Austria

Tina Bagratuni, PhD^1*, Foteini Aktypi, MSc^2*, Maria Sakkou^3,4,5*, Kleio Maria Verrou^3*, Nefeli Mavrianou-Koutsoukou, BSc^6*, Dimitrios Patseas^7*, Christine Ivy Liacos, MSc^2*, Stamatia Skourti^8*, Alexandra Papadimou^8*, Foteini Theodorakakou, MD^2*, George Kollias^3,4,5*, Petros Sfikakis, MD, PhD^3,9*, Maria Gavriatopoulou, MD^2*, Evangelos Terpos, MD, PhD², Meletios A. Dimopoulos, MD² and Efstathios Kastritis, MD^2*

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Attiki, Greece
²Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
³Center of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁴Department of Physiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁵Institute for Bioinnovation, Biomedical Sciences Research Center (BSRC) ‘Alexander Fleming’, Vari, Greece
⁶Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
⁷NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, ATHENS, Greece
⁸Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
⁹Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Luca Heinmann^1*, Helal Mohammed Mohammed Ahmed Noman, MBBS², Klara Möllers^1*, Subbaiah Chary Nimmagadda, PhD^1*, Kaiyan Sun^1*, Daria Frank, PhD^1*, Hanna Korab^3*, Lanying Wei^4*, Anja Baumann^3*, Alexandra Poos, PhD^3*, Marc-Steffen Raab^5*, Georg Lenz, Prof., MD⁶ and Cyrus Khandanpour, PD, MD¹

¹Department of Medicine A, University Hospital Muenster, Muenster, Germany
²Department of Medicine A, University Hospital Muenster, Münster, Germany
³Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁴Institute of Medical Informatics, University Hospital Muenster, Muenster, Germany., Muenster, Germany
⁵Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
⁶Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany

Emily Gallagher, MD PhD^1*, Alessandro Lagana, PhD^2,3,4,5*, Jasmine Huang, MD PhD^6,7*, David T. Melnekoff, MS^3,8,9,10*, Sundar Jagannath^{3,9,11,12,13,14,15,16} and Samir Parekh, MD^{3,17,18,19,20}

¹Icahn School of Medicine At Mount Sinai, New York, NY
²Department of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, NY
³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York
⁵Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY
⁶Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
⁹Icahn School of Medicine at Mount Sinai, New York, NY
¹⁰Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
¹¹Multiple Myeloma, Mount Sinai Cancer Institute, New York
¹²Mount Sinai Medical Center, New York, NY
¹³Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁴Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
¹⁵Mount Sinai Hospital, New York, NY
¹⁶Multiple Myeloma Research Consortium, Norwalk, CT
¹⁷Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁸Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁹Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
²⁰Mount Sinai School of Medicine, New York, NY

A. Keith Stewart, MBChB¹, Zhihua Li, MSc^2*, Olga Issakova, PhD^3*, Nikolai Sepetov, PhD^3* and Suzanne Trudel, MD²

¹University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
³Nanosyn Inc., Santa Clara, CA

Tatsuya Konishi^1*, Toshiki Ochi, MD, PhD^1,2*, Masaki Maruta, MD, PhD^1*, Kazushi Tanimoto, MD, PhD^1*, Takashi Saitou, PhD^3*, Takeshi Imamura, MD, PhD^3*, Masaki Yasukawa, MD, PhD^2,4* and Katsuto Takenaka, MD, PhD¹

¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
²Division of Immune Regulation, Proteo-Science Center, Ehime University, Ehime, Japan
³Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Ehime, Japan
⁴Ehime Prefectural University of Health Sciences, Ehime, Japan

Zachary J Walker, BS, MS^1*, Rachel N Steinmetz, BSc^2*, Denis J Ohlstrom, BS, MS^3*, Lauren T Reiman, BSc^1*, Taylor S Mills, BA¹, Beau M Idler, BA^4*, Brett M. Stevens, PhD¹, Eric Pietras, PhD¹ and Daniel W. Sherbenou, MD, PhD¹

¹Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
²Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO
³School of Medicine, Emory University, Atlanta, GA
⁴Mayo Clinic Alix School of Medicine, Scottsdale, AZ

Marija K Simic^1,2*, Sindhu T Mohanty^1*, Ya Xiao^1*, Tegan L Cheng^3*, Feng Cong^4*, Michael Daley^4*, Peter I Croucher^1,2* and Michelle M McDonald^1,2*

¹Healthy Ageing, Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
²St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia
³Centre for Children's Bone and Musculoskeletal Health, The Children's Hospital at Westmead, Westmead, NSW, Australia
⁴Novartis Institutes for Biomedical Research, Cambridge, MA

Jing Fu, PhD¹, Shirong Li, PhD^2*, Huihui Ma, MD, PhD^3*, Jun Yang, MS^2*, Lewis M Brown, PhD^4*, Gabriel M. Pagnotti, PhD^5*, Stephen J. Weiss, MD, PhD^6*, Markus Y. Mapara, MD, PhD³ and Suzanne Lentzsch, MD, PhD²

¹Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
²Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
³Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
⁴Quantitative Proteomics Center, Columbia University, New York, NY
⁵Department of Endocrine, Neoplasia and Hormonal Disorders, University of Texas - MD Anderson Cancer Center, Houston, TX
⁶Department of Internal Medicine, University of Michigan, Life Sciences Institute, Ann Arbor, MI

Maximilian Merz, MD^1*, Lei Wei, PhD^2*, Qiang Hu, PhD^1*, Almuth Maria Anni Merz, MD^2*, Jie Wang, PhD^1*, Ahmed Belal, MD^3*, Ronald Alberico, MD^3*, Cherie Rondeau, NP^1*, Kimberly Celotto, NP^1*, AnneMarie W. Block, PhD², Hemn Mohammadpour, PhD⁴, Paul K. Wallace, MS, PhD⁵, Joseph Dennis Tario, PhD^2*, Jesse Luce^3*, Sean Glenn, PhD^3*, Prashant K Singh, PhD^6*, David Barnidge, PhD^7*, Song Liu, PhD^8*, Philip L. McCarthy, MD⁹ and Jens Hillengass²

¹Roswell Park Comprehensive Cancer Center, Buffalo
²Roswell Park Comprehensive Cancer Center, Buffalo, NY
³Roswell Park Cancer Institute, Buffalo, NY
⁴Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁵Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶Center for Personalized Medicine, Roswell Park Cancer Comprehensive Cancer Center, Buffalo, NY
⁷The Binding Site Inc., Rochester, MN
⁸Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁹Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

Yuting Yan^1*, Xiaoqi Qin^2*, Jiahui Liu^3*, Huishou Fan^4*, Lanting Liu^5*, Zhen Yu^5*, Shuhui Deng, MD^3*, Wei Liu^3*, Dehui Zou^6*, Lugui Qiu³ and Gang An^7*

¹Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁴National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁵State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
⁶Department of Lymphoma & Myeloma, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences & Peking Union of Medical College, Tianjin, China
⁷Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China

Simone A Minnie, PhD^1*, Nicole S Nemychenkov^1*, Shuichiro Takahashi, MD, PhD^1*, Christine R Schmidt^1*, Samuel RW Legg^1*, Kathleen S Ensbey^1* and Geoffrey R Hill, MD^1,2

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
²Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

Zuzana Chyra^1,2,3*, Srikanth Talluri, PhD^4,5*, Rao Prabhala, PhD^4,5, Mehmet K. Samur, PhD^6,7*, Anil Aktas-Samur, PhD^8,9*, Yan Xu, MD^10,11*, Aaron B. Beeler, PhD^12*, Roman Hajek, MD, PhD^13,14,15, Mariateresa Fulciniti, PhD¹⁰, Masood A. Shammas, PhD^5,16* and Nikhil C. Munshi, MD, PhD^17,18,19

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Boston, MA
²Department of Hemato-Oncology,, University Hospital Ostrava, Ostrava, Czech Republic
³Department of Internal Studies, University of Ostrava, Ostrava, Czech Republic
⁴Dana-Farber Cancer Institute, Boston, MA
⁵VA Boston Healthcare System, Boston, MA
⁶Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁷The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Department of Data Science, Dana Farber Cancer Institute, Boston, MA
⁹Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
¹²Department of Chemistry and Center for Molecular Discovery, Boston University, Boston
¹³Czech Myeloma Group, Brno, Czech Republic
¹⁴Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
¹⁵Faculty of Medicine, Department of Clinical Studies, University of Ostrava, Ostrava, Czech Republic
¹⁶The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
¹⁷Dana-Farber Cancer Institute, Harvard Medical School, Boston
¹⁸Boston VA Healthcare System, West Roxbury, MA
¹⁹Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Aditi Sharma, PhD^1*, Abhinav Achreja, PhD^2,3*, Remya Nair, PhD^1*, Pulkit Gupta^1*, Claudia L Edgar, BS^1*, Olamide Animasahun, BS^3,4*, Anjali Mittal, BS^3,4*, Bhakti Dwivedi, PhD^5*, Manoj Bhasin, PhD⁶, Vikas A Gupta, MD, PhD^1*, Benjamin G Barwick, PhD¹, Shannon M Matulis, PhD^1*, Sagar Lonial, MD, FACP¹, Lawrence H. Boise, PhD¹, David L Jaye, MD⁷, Arun P Wiita, MD, PhD⁸, Ajay K. Nooka⁹, Deepak Nagrath, MS, PhD^2,3,4* and Mala Shanmugam, PhD¹⁰

¹Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
²Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI
³Biointerfaces Institute, University of Michigan, Ann Arbor, MI
⁴Department of Chemical Engineering, University of Michigan, Ann Arbor, MI
⁵Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA
⁶Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
⁷Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Dunwoody, GA
⁸Department of Laboratory Medicine, UCSF, San Francisco, CA
⁹Department of Hematology and Medical Oncology, Winship Cancer Insitute, Emory University School of Medicine, Atlanta, GA
¹⁰Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA

Olga Dashevsky, PhD^1,2*, Ricardo De Matos Simoes, PhD^1,2*, Benjamin G Barwick, PhD³, Sara Gandolfi, MD, PhD^1,2,4*, Ryosuke Shirasaki, MD^2,5*, Michal Sheffer, PhD^1,2*, Aedin Culhane, PhD^6*, Richard WJ Groen^7*, Aviad Tsherniak, PhD^1*, Francisca Vazquez, Phd^1*, Jonathan D. Licht, MD⁸, Lawrence H. Boise, PhD⁹ and Constantine S. Mitsiades, MD, PhD^1,2

¹Broad Institute of MIT and Harvard, Cambridge, MA
²Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
⁴Translational Immunology Research program, University of Helsinki, Helsinki, MA, Finland
⁵Dept. of Medical Oncology, Teikyo university hospital, Tokyo, TKY, Japan
⁶Dept. of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷VU University Medical Center, Amsterdam, NLD
⁸Department of Medicine, University of Florida, Gainesville, FL
⁹Emory University, Atlanta, GA

Chad C Bjorklund, PhD^1*, Michael Amatangelo, PhD^2*, Hsiling Chiu, MS^2*, Jian Kang^3*, Tiziana Civardi^4*, Jessica Katz, MD PhD^3*, Paulo Maciag, MD PhD^3*, Patrick Hagner, PhD^3*, Michael Pourdehnad, MD PhD^5*, Nizar J. Bahlis, MD⁶, Paul G. Richardson, MD^7,8 and Anjan Thakurta, PhD^9*

¹Translational Medicine-Hematology, Bristol Myers-Squibb, SUMMIT, NJ
²Bristol Myers Squibb, Summit, NJ
³Bristol Myers Squibb, Princeton, NJ
⁴Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
⁵Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, Princeton, NJ
⁶Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
⁷Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
⁸Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ

Cristina Panaroni, PhD¹, Keertik Fulzele, PhD^2*, Tomoaki Mori, MD, PhD^3*, Rie Nakamoto-Matsubara, MD, PhD^3*, Allison Maebius, MSc^3* and Noopur S. Raje, MD³

¹Center for Multiple Myeloma, Massachusetts General Hospital - Cancer Center, Boston, MA
²Constellation Pharma, Cambridge, MA
³Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA

Sayak Chakravarti, MSc, BSc^1*, Suman Mazumder, PhD^2,3*, Harish Kumar, PhD², Neeraj Sharma, PhD^4*, Ujjal Kumar Mukherjee, PhD^5*, Shaji K Kumar, MD⁶, Linda B Baughn, PhD⁷, Brian G. Van Ness, PhD⁸ and Amit Kumar Mitra, PhD, MSc, BSc^2,3

¹Harrison School of Pharmacy, Auburn, AUBURN, AL
²Harrison School of Pharmacy, Auburn University, Auburn, AL
³Center for Pharmacogenomics and Integrated Omics Initiative, Auburn University, Auburn, AL
⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁵University of Illinois - Urbana Champaign, Champaign, IL
⁶Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
⁷Division of Laboratory Genetics, Mayo Clinic, Rochester, MN
⁸Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN